MAIA Biotechnology

MAIA Biotechnology is an operating biopharmaceutical company, not an investment firm. Capital allocation decisions rest with CEO Vlad Vitoc and the board of directors, who oversee the public company's budget and clinical-trial financing strategy. The firm's spending is directed almost entirely toward R&D, with no external fund commitments or LP-driven investment mandates.

MAIA does not source deals in the traditional investment sense; its pipeline originates from in-house research into telomere-targeting mechanisms. The company's scientific team identifies and validates new chemical entities targeting telomerase, filing its own patents and advancing leads toward Investigational New Drug applications. Occasional in-licensing of complementary technologies supplements the internal discovery engine.

Neither. MAIA is a publicly traded clinical-stage biotech corporation listed on the NYSE American since 2022. It raises capital through equity offerings rather than managing a single family's wealth or investing in third-party startups. Its sole focus is developing anticancer therapies from its own research.

MAIA is not an investment manager and does not deploy capital into fund commitments, direct co-investments, or real assets. The firm's balance sheet is allocated to clinical development, manufacturing, and intellectual property related to its oncology programs. External collaborations are structured as research agreements rather than financial investments.

Funding comes from public equity raises, including its 2022 initial public offering and subsequent at-the-market facilities, supplemented by National Cancer Institute grants and potential licensing revenue. The company has not disclosed backing from a single-family source or sovereign wealth entity, distinguishing it from privately capitalized family office biotech ventures.